WEST LAFAYETTE, Ind. (AP) _ Endocyte Inc. (ECYT) on Wednesday reported a loss of $12.6 million in its third quarter.
On a per-share basis, the West Lafayette, Indiana-based company said it had a loss of 17 cents.
The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 16 cents per share.
The biopharmaceutical company posted revenue of $86,000 in the period.
Endocyte shares have climbed fivefold since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $23.66, increasing fivefold in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ECYT at https://www.zacks.com/ap/ECYT